CERTIFICATE OF MAILING										
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, PO Box 1450, Alexandria VA 22313-1450										
Jennifer China	Sauty I sun	November 12, 2003								
Type or print name	Signature'	Date								

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF MORRIS ET AL. APPLICATION NO:

FILED: NOVEMBER 12, 2003

FOR: METHODS AND KITS FOR ASSAYS OF RAPID SCREENING. OF

DIABETES

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the filing date of the application.

Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. CL/V-32765A APPLICATION NO.

APPLICANT
MORRIS ET AL.
FILING DATE
NOVEMBER 12, 2003

Group

			U.S.	PATENT D	OCUMENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILI	NG DATE
	AA								
	AB						*****		
	AC								
	AD								
	AE								
	AF								
	AG								
	АН								
**	Al								
	AJ								
	AK								
	AL								
			FOREIG	N PATEN	T DOCUMENTS	3			
-		DOCUMENT NUMBER	DATE		OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	АМ								
	AN								
	AO								
	AP								
	AQ								
		OTHER DOC	JMENTS	(Including A	uthor, Title, Date, F	ertinent pages, E	tc.)		
	AR	Abstract: Diagnosing period presence in tea	latent form rs after spe	of diabetes cified perio	mellitus - by ad od, using indicat	lministering glu or paper. By D	cose and tes erwent 2002	ting fo	r its
	AS							· · · ·	
	АТ								

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Agent for Applicants

Reg. No. 41,422

Novartis Pharmaceuticals Corporation Patent and Trademark Dept. One Health Plaza East Hanover, NJ 07936-1080 (678) 415-4691

Date: November 12, 2003